This article is more than 5 years old. Information may no longer be current.

Long-term study finds latanoprost reduced IOP, maintained visual fields in Japanese patients

J Glaucoma. 2008;17(8):662-666.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Latanoprost monotherapy lowered IOP and maintained visual fields after 5 years of treatment in approximately 70% of glaucoma patients in a study.

The study examined latanoprost alone in 72 eyes of 72 Japanese patients. Of those, 47 eyes had normal tension glaucoma and 25 had primary open-angle glaucoma. The study's mean duration of latanoprost monotherapy was 4.1± 2 years.

Clinicians found that the reduction of IOP, relative to the mean IOP of 17.8 ? 3.4 mm Hg before latanoprost monotherapy, was 11.5% at 6 months; 15.5% at 1 year; 13% at 2 years; 13.4% at 3 years; 13.5% at 4 years; and 10.6% at 5 years. Latanoprost showed the best results in primary open-angle glaucoma patients, the study authors said.

"Although latanoprost demonstrated significant IOP reduction in [primary open-angle glaucoma] and [normal tension glaucoma], eyes with [primary open-angle glaucoma] showed significant IOP reduction than those with [normal tension glaucoma]," they said.

Two eyes had local adverse events after latanoprost was stopped, and four eyes required filtering surgery.